To the best of our knowledge, this is the first study to classify patients with NSCLC according to the Fleischner Society ILA subtypes and to demonstrate subtype-associated risk with respect to radiotherapy outcomes. This evidence concerns the gene TNFRSF9 and non-small cell lung carcinoma.